OpenEvidence
| Company type | Private |
|---|---|
| Industry | Artificial intelligence, Healthcare |
| Founded | 2022 |
| Founder | Daniel Nadler, Zachary Ziegler |
| Headquarters | Miami , United States |
Key people | Daniel Nadler (Co-founder), Zachary Ziegler (Co-founder) |
| Products | AI-powered medical search platform, DeepConsult |
OpenEvidence is a U.S.-based artificial intelligence firm specializing in the creation of a medical search platform designed to aid clinical decision-making. Established in 2022 by entrepreneur Daniel Nadler alongside co-founder Zachary Ziegler, the company operates out of its headquarters in Miami, Florida.
History
The inception of OpenEvidence traces back to Daniel Nadler, who holds a Ph.D. from Harvard and previously founded Kensho, a financial analytics company acquired by S&P Global in 2018. Nadler collaborated with Harvard machine learning expert Zachary Ziegler to address the difficulties healthcare professionals encounter when navigating the expanding body of medical research.
In 2023, OpenEvidence’s artificial intelligence system achieved a 90% score on the United States Medical Licensing Examination (USMLE), outperforming rivals such as ChatGPT and Med-PaLM 2. That same year, the company took part in the Mayo Clinic health-tech accelerator program. By 2025, their AI model reached an unprecedented perfect score of 100% on the USMLE.
In February 2025, OpenEvidence completed a Series A financing round led by Sequoia Capital, raising $75 million and reaching a valuation of $1 billion. Later, in July 2025, it secured $210 million through a funding round spearheaded by GV (Google Ventures) and Kleiner Perkins, with additional investments from Coatue, Conviction, and Thrive Capital, which elevated its valuation to $3.5 billion.
The company has established key collaborations with prominent organizations including the American Medical Association, The New England Journal of Medicine, as well as specialty publications within the JAMA Network.
On October 20, 2025, OpenEvidence announced the closing of a $200 million Series C funding round that valued the enterprise at $6 billion.
Product and technology
OpenEvidence provides an AI-powered platform designed to evaluate and systematically organize peer-reviewed medical research from premier clinical publications such as The New England Journal of Medicine and The Journal of the American Medical Association. Verified physicians can access the service at no cost, while the company’s income is derived from advertising. By July 2025, the platform had attracted more than 430,000 registered U.S. physicians, representing nearly 40% of the national physician population, and facilitated over 8.5 million consultations each month. During this timeframe, OpenEvidence introduced DeepConsult, a tool that employs reasoning algorithms to integrate results from multiple studies.
Recognition
In 2025, Daniel Nadler, co-founder of OpenEvidence, was honored on the TIME100 Health list, which highlights the 100 most impactful figures in global health.